+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Forecast 2023-2030

  • PDF Icon

    Report

  • 193 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4986033
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Viral Vector & Plasmid DNA Manufacturing Market size was estimated at USD 1.20 billion in 2022, USD 1.50 billion in 2023, and is expected to grow at a CAGR of 25.30% to reach USD 7.32 billion by 2030.

The market of viral vector and plasmid DNA manufacturing encompasses the production of plasmid DNA and viral vectors used for gene delivery to develop gene therapies and genetically modified organisms. Viral vectors are tools that molecular biologists use to produce genetic material in cells. This procedure can be completed inside a living organism (in vivo) or cell culture (ex vivo). Meanwhile, plasmid DNA is a small circular DNA strand that can be used to transfer genetic material similarly. Applications for these products range significantly and include clinical gene therapy for hereditary diseases, genetic vaccines, and cancer treatment strategies. End-users of viral vector and plasmid DNA products include pharmaceutical and biopharmaceutical companies, academic and research institutions, and clinical research organizations. The evolution of the viral vector and plasmid DNA manufacturing market is influenced by the increasing number of gene therapy candidates entering clinical trials, advancement in molecular biology technologies, rising investment in personalized medicine, and the growing prevalence of targeted diseases. The commitment of regulatory agencies to fast-track approvals for emerging therapies also supports market expansion. However, the market faces certain challenges, such as the high manufacturing cost due to complex production methods, regulatory hurdles, concerns regarding the safety and efficacy of gene therapy products, and the need for highly specialized technical expertise. On the other hand, the latest potential opportunities in the market include developments in vector design to reduce immunogenicity, increases in scale-up production processes to meet market demands, and advancements in gene-editing tools such as CRISPR/Cas9. Emerging economies expanding their biotechnological sectors also present significant opportunities for market players.

Regional Insights

The Americas, particularly the United States, remain at the forefront of biopharmaceutical research, including developing and manufacturing viral vectors and plasmid DNA. Recent investments and initiatives, such as launching advanced therapy production facilities and federal funding for gene therapy manufacturing, underscore the region's capacity in this field. Canada also contributes significantly, with its collaborative approach between academia and industry facilitating advanced research and development in this sector. The EU countries have been proactive in fostering a conducive environment for the growth of advanced therapy medicinal products (ATMPs), which include gene therapies employing viral vectors and plasmid DNA. Customer purchasing behavior in Europe is often influenced by the alignment of product offerings to these regulatory incentives and the established healthcare systems supporting innovative treatments. The Middle East, while still developing in this field, is seeing increased interest and investment in biotechnology, leading to a gradual increase in regional capabilities for manufacturing viral vectors and plasmid DNA. On the other hand, Africa presents a diverse picture, with South Africa heading in research capabilities, albeit on a smaller scale than global leaders. In APAC, China's commitment to biotech innovation is evident in its growing presence in the viral vector and plasmid DNA manufacturing landscape, supported by substantial government investments in research infrastructure and favorable policies for biotech companies. The country's fast-growing biotech sector translates to strong consumer demand and aggressive customer purchasing behavior towards local and international partnerships and technologies. India, while an emerging player in this field, is experiencing burgeoning demand due to its large population and increasing focus on healthcare innovation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Viral Vector & Plasmid DNA Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Viral Vector & Plasmid DNA Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Viral Vector & Plasmid DNA Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc., Akron Biotech, Avid Bioservices, Inc., Batavia Biosciences B.V., BioNTech IMFS GmbH, Biovian Oy, c-LEcta GmbH, Charles River Laboratories International, Inc., Creative Biogene, FILTROX AG, Forge Biologics By Ajinomoto Co., Inc., FUJIFILM Diosynth Biotechnologies Inc., GE HealthCare Technologies, Inc., GeneOne Life Science, Inc., Genezen, Genezen Laboratories, Inc., Kaneka Eurogentec S.A., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, PerkinElmer Inc., REGENXBIO Inc., Spark Therapeutics, Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uniQure N.V., and Wuxi AppTec Co., Ltd.

Market Segmentation & Coverage

This research report categorizes the Viral Vector & Plasmid DNA Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Plasmid DNA
    • Viral Vector
      • Adeno-Associated Virus
      • Adenovirus
      • Lentivirus
  • Cell Line
    • In-vitro
    • In-Vivo
  • Transfection
    • Stable Transfection
    • Transient Transfection
  • Indication
    • Cancer
    • Genetic Disorder
    • Infectious Disease
  • Workflow
    • Downstream Processing
      • Fill-finish
      • Purification
    • Upstream Processing
      • Vector Amplification & Expansion
      • Vector Recovery/Harvesting
  • Application
    • Cell Therapy
    • Gene Therapy
    • Vaccinology
  • End User
    • Pharmaceutical & Biopharmaceutical Companies
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Viral Vector & Plasmid DNA Manufacturing Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Viral Vector & Plasmid DNA Manufacturing Market?
  3. What are the technology trends and regulatory frameworks in the Viral Vector & Plasmid DNA Manufacturing Market?
  4. What is the market share of the leading vendors in the Viral Vector & Plasmid DNA Manufacturing Market?
  5. Which modes and strategic moves are suitable for entering the Viral Vector & Plasmid DNA Manufacturing Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Viral Vector & Plasmid DNA Manufacturing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing number of gene therapy clinical trials worldwide
5.1.1.2. Growing advancement in molecular biology technologies
5.1.2. Restraints
5.1.2.1. High cost of manufacturing of viral vector & plasmid DNA solutions
5.1.3. Opportunities
5.1.3.1. Growing introduction of novel viral vector & plasmid DNA solutions
5.1.3.2. Rising investment in personalized medicine
5.1.4. Challenges
5.1.4.1. Concerns regarding the safety and efficacy of gene therapy products
5.2. Market Segmentation Analysis
5.2.1. Cell Line: Growing usage of in-vitro cell lines in controlled laboratory environments
5.2.2. Type: Increasing need for plasmid DNA manufacturing to deliver genetic material into cells
5.2.3. Transfection: Rising popularity of stable transfection for gene therapy and drug development
5.2.4. End User: Expanding the potential of viral vectors & plasmid DNA across pharmaceutical & biopharmaceutical companies for the development and production of next-generation vaccines
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Viral Vector & Plasmid DNA Manufacturing Market, by Type
6.1. Introduction
6.2. Plasmid DNA
6.3. Viral Vector
6.4.1. Adeno-Associated Virus
6.4.2. Adenovirus
6.4.3. Lentivirus
7. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line
7.1. Introduction
7.2. In-vitro
7.3. In-Vivo
8. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection
8.1. Introduction
8.2. Stable Transfection
8.3. Transient Transfection
9. Viral Vector & Plasmid DNA Manufacturing Market, by Indication
9.1. Introduction
9.2. Cancer
9.3. Genetic Disorder
9.4. Infectious Disease
10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow
10.1. Introduction
10.2. Downstream Processing
10.3.1. Fill-finish
10.3.2. Purification
10.3. Upstream Processing
10.4.1. Vector Amplification & Expansion
10.4.2. Vector Recovery/Harvesting
11. Viral Vector & Plasmid DNA Manufacturing Market, by Application
11.1. Introduction
11.2. Cell Therapy
11.3. Gene Therapy
11.4. Vaccinology
12. Viral Vector & Plasmid DNA Manufacturing Market, by End User
12.1. Introduction
12.2. Pharmaceutical & Biopharmaceutical Companies
12.3. Research Institutes
13. Americas Viral Vector & Plasmid DNA Manufacturing Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.2. Market Share Analysis, By Key Player
16.3. Competitive Scenario Analysis, By Key Player
16.3.1. Merger & Acquisition
16.3.1.1. Ajinomoto Co., Inc. to Acquire Forge Biologics for USD 620 Million
16.3.2. Agreement, Collaboration, & Partnership
16.3.2.1. CCRM Partners with Membio to Streamline Production of Viral Vectors for Cell and Gene Therapies
16.3.3. Investment & Funding
16.3.3.1. Genezen Secures USD 18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities
17. Competitive Portfolio
17.1. Key Company Profiles
17.1.1. Advanced BioScience Laboratories, Inc.
17.1.2. Akron Biotech
17.1.3. Avid Bioservices, Inc.
17.1.4. Batavia Biosciences B.V.
17.1.5. BioNTech IMFS GmbH
17.1.6. Biovian Oy
17.1.7. c-LEcta GmbH
17.1.8. Charles River Laboratories International, Inc.
17.1.9. Creative Biogene
17.1.10. FILTROX AG
17.1.11. Forge Biologics By Ajinomoto Co., Inc.
17.1.12. FUJIFILM Diosynth Biotechnologies Inc.
17.1.13. GE HealthCare Technologies, Inc.
17.1.14. GeneOne Life Science, Inc.
17.1.15. Genezen
17.1.16. Genezen Laboratories, Inc.
17.1.17. Kaneka Eurogentec S.A.
17.1.18. Lonza Group Ltd.
17.1.19. Merck KGaA
17.1.20. Miltenyi Biotec B.V. & Co. KG
17.1.21. PerkinElmer Inc.
17.1.22. REGENXBIO Inc.
17.1.23. Spark Therapeutics, Inc.
17.1.24. Takara Bio Inc.
17.1.25. Thermo Fisher Scientific Inc.
17.1.26. uniQure N.V.
17.1.27. Wuxi AppTec Co., Ltd.
17.2. Key Product Portfolio
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2022 VS 2030
FIGURE 3. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET DYNAMICS
FIGURE 7. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2022 VS 2030 (%)
FIGURE 10. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2022 VS 2030 (%)
FIGURE 12. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 14. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2022 VS 2030 (%)
FIGURE 16. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 18. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 20. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 24. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 29. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 30. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2022

Companies Mentioned

  • Advanced BioScience Laboratories, Inc.
  • Akron Biotech
  • Avid Bioservices, Inc.
  • Batavia Biosciences B.V.
  • BioNTech IMFS GmbH
  • Biovian Oy
  • c-LEcta GmbH
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • FILTROX AG
  • Forge Biologics By Ajinomoto Co., Inc.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • GE HealthCare Technologies, Inc.
  • GeneOne Life Science, Inc.
  • Genezen
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec S.A.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec B.V. & Co. KG
  • PerkinElmer Inc.
  • REGENXBIO Inc.
  • Spark Therapeutics, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure N.V.
  • Wuxi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Table Information